WuXi opens continuous manufacturing line for oral solids

By Ben Hargreaves

- Last updated on GMT

© samxmeg / Getty Images
© samxmeg / Getty Images

Related tags Wuxi China WuXi STA Continuous manufacturing

The CDMO announces the launch of its first drug product continuous manufacturing line for oral solids, located in Wuxi City, China.

WuXi STA, a subsidiary of WuXi AppTec, opened the new continuous manufacturing line and confirmed that it had already begun operations. The line is located within the company’s formulation development and manufacturing campus in Wuxi City.

The continuous manufacturing line features continuous direct compression equipment with unit operations including dispensing, blending, lubrication, tablet compression, and coating.

WuXi STA states that the process analytical technology (PAT) is implemented within the continuous manufacturing line to monitor blending uniformity. The technology utilized also allows for real-time analysis and control during production to monitor product quality.

The contract development and manufacturing organization (CDMO) outlined that adding the continuous manufacturing line should enable higher yields to be achieved and to ensure shorter timelines to market for clients developing oral drug solutions.

The move by WuXi STA comes as there is a general push in the direction towards greater adoption of continuous technology across the industry, both from the larger CDMOs and from regulators​. This move is being promoted by multiple factors​: the flexibility of the approach, the ability to reduce costs, and potential improvements to efficiency.

For WuXi STA, the decision to add the continuous manufacturing line comes amid a broader push to build out its operations in oral solid dosage forms.

In December 2022​, the company announced that it had completed adding a parenteral formulation manufacturing line for oral solid dosage forms to its drug product site in Wuxi City. This addition represented the second time during the same year that WuXi STA had expanded the number of manufacturing lines at the facility.

At a different location, in Changzhou, China, the company also opened a high-potency active pharmaceutical ingredient (HPAPI) plant. At the time​, Youchu Wang, head of early stage development at WuXi STA, told Outsourcing-Pharma, “Specific to HPAPI capability and capacity, our expansion won’t stop at this new plant in Changzhou. We announced our new 170-acre Taixing site in Jiangsu China last year. We will build more HPAPI plants in Taixing in the next few years.”

Wider than HPAPIs, Wang confirmed that the company is ‘continuously expanding’ capabilities in small molecule drug manufacturing and new treatment modalities, including oligonucleotides, peptides, and their conjugates.

As such, the company will open a new high potency parenteral manufacturing line in the third quarter of 2023, located in the Wuxi City campus.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us


View more